Security
Corvus Pharmaceuticals, Inc. Common Stock · CRVS
CRVSNASDAQCommon stockCurrentCIK 1626971Updated Oct 6, 2026
CRVS price & chart
Loading TradingView…
NASDAQ:CRVS on TradingView ↗About the company
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
In the news
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 80,474,000Source | 58,815,000Source | 239,274,000Source | 89,461,000Source | 64,561,000Source | 253,195,000Source | 59,438,000Source | 40,084,000Source | 71,119,000Source | 68,907,000Source | 45,553,000Source | 68,240,000Source |
| Property, Plant and Equipment, NetUSD | 221,000Source | 171,000Source | 830,000Source | 249,000Source | 192,000Source | 282,000Source | 165,000Source | 213,000Source | 220,000Source | 151,000Source | 236,000Source | 353,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,867,000Source | 4,680,000Source | 18,905,000Source | 14,691,000Source | 14,841,000Source | 40,102,000Source | 4,999,000Source | 7,456,000Source | 4,576,000Source | 8,740,000Source | 12,620,000Source | 13,159,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 32,000Source | 70,000Source | 6,000Source | 86,000Source | 35,000Source | 43,000Source | 79,000Source | 26,000Source | 37,000Source | 75,000Source | 26,000Source | 588,000Source |
| Assets, CurrentUSD | 66,944,000Source | 42,921,000Source | 220,965,000Source | 75,780,000Source | 48,258,000Source | 239,946,000Source | 45,491,000Source | 22,851,000Source | 58,214,000Source | 54,407,000Source | 27,956,000Source | 43,664,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,223,000Source | 1,200,000Source | 5,731,000Source | 1,287,000Source | 977,000Source | 3,189,000Source | 1,200,000Source | 697,000Source | 1,427,000Source | 2,368,000Source | 781,000Source | 773,000Source |
| Operating Lease, Right-of-Use AssetUSD | 927,000Source | 284,000Source | 659,000Source | 1,012,000Source | 578,000Source | 751,000Source | 1,095,000Source | 865,000Source | 839,000Source | 1,177,000Source | 1,149,000Source | 2,217,000Source |
| Other Assets, NoncurrentUSD | 852,000Source | 252,000Source | 1,713,000Source | 626,000Source | 129,000Source | 1,720,000Source | 629,000Source | 89,000Source | 855,000Source | 632,000Source | 89,000Source | 129,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 8,706,000Source | 46,406,000Source | 13,946,000Source | 9,233,000Source | 13,335,000Source | 12,516,000Source | 10,113,000Source | 6,720,000Source | 9,914,000Source | 36,339,000Source | 6,869,000Source | 12,125,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 7,000Source | 6,000Source | 8,000Source | 7,000Source | 6,000Source | 8,000Source | 7,000Source | 5,000Source | 7,000Source | 7,000Source | 5,000Source | 5,000Source |
| Additional Paid in CapitalUSD | — | — | 670,557,000Source | — | — | 667,782,000Source | — | — | 474,387,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -399,972,000Source | -384,897,000Source | -443,944,000Source | -389,815,000Source | -344,680,000Source | -425,985,000Source | -381,817,000Source | -340,418,000Source | -412,293,000Source | -397,010,000Source | -334,717,000Source | -307,688,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,060,000Source | -738,000Source | -1,293,000Source | -1,148,000Source | -1,355,000Source | -1,126,000Source | -1,254,000Source | -1,275,000Source | -896,000Source | -1,288,000Source | -967,000Source | -563,000Source |
| Stockholders' Equity Attributable to ParentUSD | 71,768,000Source | 12,409,000Source | 225,328,000Source | 80,228,000Source | 51,226,000Source | 240,679,000Source | 49,325,000Source | 33,364,000Source | 61,205,000Source | 32,568,000Source | 38,684,000Source | 56,115,000Source |
| Additional Paid in Capital, Common StockUSD | 472,793,000Source | 398,038,000Source | — | 471,184,000Source | 397,255,000Source | — | 432,389,000Source | 375,052,000Source | — | 430,859,000Source | 374,363,000Source | 364,361,000Source |
| Liabilities and EquityUSD | 80,474,000Source | 58,815,000Source | 239,274,000Source | 89,461,000Source | 64,561,000Source | 253,195,000Source | 59,438,000Source | 40,084,000Source | 71,119,000Source | 68,907,000Source | 45,553,000Source | 68,240,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 8,074,000Source | 46,406,000Source | 13,672,000Source | 8,505,000Source | 13,335,000Source | 12,110,000Source | 9,279,000Source | 6,720,000Source | 9,380,000Source | 35,402,000Source | 6,869,000Source | 10,752,000Source |
| Operating Lease, Liability, CurrentUSD | 379,000Source | 354,000Source | 454,000Source | 355,000Source | 700,000Source | 428,000Source | 319,000Source | 1,040,000Source | 403,000Source | 185,000Source | 1,374,000Source | 1,228,000Source |
| Accounts Payable, CurrentUSD | 1,974,000Source | 1,873,000Source | 4,047,000Source | 3,137,000Source | 1,213,000Source | 4,697,000Source | 1,308,000Source | 1,609,000Source | 2,491,000Source | 2,582,000Source | 1,525,000Source | 1,976,000Source |
| Operating Lease, Liability, NoncurrentUSD | 632,000Source | — | 274,000Source | 728,000Source | — | 406,000Source | 834,000Source | — | 534,000Source | 937,000Source | — | 1,373,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,721,000Source | — | 9,171,000Source | 5,013,000Source | — | 6,985,000Source | 3,871,000Source | — | 6,486,000Source | 3,725,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 65,700,000Source | 41,700,000Source | 215,200,000Source | 74,400,000Source | 47,200,000Source | 236,700,000Source | 44,200,000Source | 22,100,000Source | 56,800,000Source | 52,000,000Source | 27,100,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -13,692,000Source | 15,193,000Source | -15,283,000Source | -62,293,000Source | -27,029,000Source | -41,307,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 29,000Source | 22,000Source | 105,000Source | 85,000Source | 151,000Source | 367,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,650,000Source | 1,251,000Source | 5,330,000Source | 3,003,000Source | 2,147,000Source | 2,692,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 2,206,000Source | -1,274,000Source | -91,000Source | 1,057,000Source | -451,000Source | 411,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -10,374,000Source | -8,263,000Source | -32,797,000Source | -25,424,000Source | -23,935,000Source | -27,023,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -144,846,000Source | 4,243,000Source | -7,796,000Source | -27,484,000Source | 15,541,000Source | -23,276,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 91,000Source | 36,000Source | 174,000Source | — | 34,000Source | 269,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 190,746,000Source | 279,000Source | 36,429,000Source | 49,028,000Source | 7,855,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 35,526,000Source | -3,741,000Source | -4,164,000Source | -3,880,000Source | -539,000Source | -50,299,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 2,867,000Source | 4,680,000Source | 18,905,000Source | 14,691,000Source | 40,102,000Source | 4,999,000Source | 4,576,000Source | 8,740,000Source | 12,620,000Source | 13,159,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,249,000Source | 733,000Source | 2,609,000Source | 1,256,000Source | 2,650,000Source | 1,251,000Source | 5,330,000Source | 3,003,000Source | 2,147,000Source | 2,692,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 65,700,000Source | 41,700,000Source | 215,200,000Source | 74,400,000Source | 236,700,000Source | 44,200,000Source | 56,800,000Source | 52,000,000Source | 27,100,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | 100,000Source | 100,000Source | 200,000Source | 400,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | -5,284,000Source | -10,005,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 5,000Source | — | 22,000Source |
| General and Administrative ExpenseUSD | — | — | 2,118,000Source | 2,033,000Source | 3,333,000Source | 2,387,000Source | 3,702,000Source | 2,469,000Source | 9,252,000Source | 8,163,000Source | 6,881,000Source | 8,097,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -323,000Source | -682,000Source | -709,000Source | -389,000Source | -599,000Source | -539,000Source | -1,958,000Source | -3,197,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,157,000Source | -40,217,000Source | -17,959,000Source | -7,998,000Source | -13,692,000Source | 15,193,000Source | -15,283,000Source | -62,293,000Source | -27,029,000Source | -41,307,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,157,000Source | -40,217,000Source | -17,959,000Source | -7,998,000Source | -13,692,000Source | 15,193,000Source | -15,283,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 10,572,000Source | 7,255,000Source | 19,297,000Source | 10,260,000Source | 14,877,000Source | 9,922,000Source | 42,971,000Source | 27,548,000Source | 23,407,000Source | 32,565,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 189,407,000Source | — | — | 16,405,000Source | — | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 16,982,000Source | 11,987,000Source | 84,128,000Source | 42,630,000Source | 62,623,000Source | 43,162,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,339,000Source | 279,000Source | 684,000Source | 68,000Source | 12,000Source | — |
| Nonoperating Income (Expense) | — | — | —Source | —Source | — | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -10,572,000Source | -7,255,000Source | -19,297,000Source | -10,260,000Source | -14,877,000Source | -9,922,000Source | -42,971,000Source | -27,548,000Source | -23,407,000Source | -32,565,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -10,157,000Source | -40,217,000Source | -17,959,000Source | -7,998,000Source | -13,692,000Source | 15,193,000Source | -15,283,000Source | -62,293,000Source | -27,029,000Source | -41,307,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.12Source | -0.6Source | -0.19Source | -0.1Source | -0.15Source | 0.21Source | -0.19Source | -1.02Source | -0.56Source | -0.89Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.12Source | -0.6Source | -0.19Source | -0.1Source | -0.15Source | -0.13Source | -0.53Source | -1.02Source | -0.56Source | -0.89Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 82,836,369Source | 66,701,086Source | 92,368,013Source | 77,774,344Source | 89,996,728Source | 72,126,496Source | 78,964,842Source | 60,985,165Source | 48,025,274Source | 46,553,511Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 82,836,369Source | 66,701,086Source | 92,368,013Source | 77,774,344Source | 89,996,728Source | 75,152,514Source | 79,742,685Source | 60,985,165Source | 48,025,274Source | 46,553,511Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 28,000Source | 20,000Source | 34,000Source | 29,000Source | 29,000Source | 22,000Source | 100,000Source | 100,000Source | 200,000Source | 400,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | -5,284,000Source | -10,005,000Source |
| General and Administrative ExpenseUSD | — | — | 2,118,000Source | 2,033,000Source | 3,333,000Source | 2,387,000Source | 3,702,000Source | 2,469,000Source | 9,252,000Source | 8,163,000Source | 6,881,000Source | 8,097,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -15,283,000Source | -62,293,000Source | -27,029,000Source | -41,307,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | -323,000Source | -682,000Source | -709,000Source | -389,000Source | -599,000Source | -539,000Source | -1,958,000Source | -3,197,000Source | — | — |
| Investment Income, NetUSD | — | — | 738,000Source | 566,000Source | 2,047,000Source | 639,000Source | 1,784,000Source | 525,000Source | 2,505,000Source | 1,824,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -10,157,000Source | -40,217,000Source | -17,959,000Source | -7,998,000Source | -13,692,000Source | 15,193,000Source | -15,283,000Source | — | — | — |
| Operating ExpensesUSD | — | — | 10,572,000Source | 7,255,000Source | 19,297,000Source | 10,260,000Source | 14,877,000Source | 9,922,000Source | 42,971,000Source | 27,548,000Source | 23,407,000Source | 32,565,000Source |
| Research and Development ExpenseUSD | — | — | 8,454,000Source | 5,222,000Source | 15,964,000Source | 7,873,000Source | 11,175,000Source | 7,453,000Source | 33,719,000Source | 19,385,000Source | 16,526,000Source | 24,468,000Source |
| Nonoperating Income (Expense) | — | — | —Source | —Source | — | —Source | —Source | —Source | — | — | — | — |
| Other General and Administrative Expense | — | — | —Source | —Source | — | —Source | —Source | —Source | — | — | — | — |
| Other General Expense | — | — | —Source | —Source | — | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-292864
Filing attachments
d12146687_ex99-1.htm · SCHEDULE 13G · 2026-05-15
EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗tm263501d4_ex99-1.htm · 8-K · 2026-01-20
Exhibit 99.1 Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following longer 8-week treatment 75% of soquelitinib patients achieved EASI 75, 25% achieved EASI 90 and 33% achieved IGA 0/1 Cohort 1-4 have demonstrated positive safety and efficacy results in patients wh…
Read attachment ↗